Sygdomsmekanismer og nye behandlingsmetoder ved migræne

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Sygdomsmekanismer og nye behandlingsmetoder ved migræne. / Hansen, Jakob Møller; Ashina, Messoud.

I: Ugeskrift for Laeger, Bind 178, V07160507, 2016.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hansen, JM & Ashina, M 2016, 'Sygdomsmekanismer og nye behandlingsmetoder ved migræne', Ugeskrift for Laeger, bind 178, V07160507. <http://ugeskriftet.dk/videnskab/sygdomsmekanismer-og-nye-behandlingsmetoder-ved-migraene>

APA

Hansen, J. M., & Ashina, M. (2016). Sygdomsmekanismer og nye behandlingsmetoder ved migræne. Ugeskrift for Laeger, 178, [V07160507]. http://ugeskriftet.dk/videnskab/sygdomsmekanismer-og-nye-behandlingsmetoder-ved-migraene

Vancouver

Hansen JM, Ashina M. Sygdomsmekanismer og nye behandlingsmetoder ved migræne. Ugeskrift for Laeger. 2016;178. V07160507.

Author

Hansen, Jakob Møller ; Ashina, Messoud. / Sygdomsmekanismer og nye behandlingsmetoder ved migræne. I: Ugeskrift for Laeger. 2016 ; Bind 178.

Bibtex

@article{e55dae806f6e4d8cb1d1c21a176cface,
title = "Sygdomsmekanismer og nye behandlingsmetoder ved migr{\ae}ne",
abstract = "Migraine is the most prevalent disabling neurological disorder. The management of patients with migraine has been hampered by lack of effective and well-tolerated acute and preventive therapies. Based on improved insights into the basic mechanisms of migraine, new and targeted treatments are currently undergoing large-scale testing. Among the most promising agents for migraine prevention are humanized antibodies against calcitonin gene-related peptide (CGRP) or the CGRP receptor. If proven effective, these new treatments may emerge to improve the lives of millions of individuals worldwide disabled by migraine.",
keywords = "Journal Article, English Abstract",
author = "Hansen, {Jakob M{\o}ller} and Messoud Ashina",
year = "2016",
language = "Dansk",
volume = "178",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",

}

RIS

TY - JOUR

T1 - Sygdomsmekanismer og nye behandlingsmetoder ved migræne

AU - Hansen, Jakob Møller

AU - Ashina, Messoud

PY - 2016

Y1 - 2016

N2 - Migraine is the most prevalent disabling neurological disorder. The management of patients with migraine has been hampered by lack of effective and well-tolerated acute and preventive therapies. Based on improved insights into the basic mechanisms of migraine, new and targeted treatments are currently undergoing large-scale testing. Among the most promising agents for migraine prevention are humanized antibodies against calcitonin gene-related peptide (CGRP) or the CGRP receptor. If proven effective, these new treatments may emerge to improve the lives of millions of individuals worldwide disabled by migraine.

AB - Migraine is the most prevalent disabling neurological disorder. The management of patients with migraine has been hampered by lack of effective and well-tolerated acute and preventive therapies. Based on improved insights into the basic mechanisms of migraine, new and targeted treatments are currently undergoing large-scale testing. Among the most promising agents for migraine prevention are humanized antibodies against calcitonin gene-related peptide (CGRP) or the CGRP receptor. If proven effective, these new treatments may emerge to improve the lives of millions of individuals worldwide disabled by migraine.

KW - Journal Article

KW - English Abstract

M3 - Tidsskriftartikel

C2 - 28041540

VL - 178

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V07160507

ER -

ID: 181027284